285 related articles for article (PubMed ID: 31983532)
1. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
[TBL] [Abstract][Full Text] [Related]
2. Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
Hilario A; Hernandez-Lain A; Sepulveda JM; Lagares A; Perez-Nuñez A; Ramos A
Neurocirugia (Astur : Engl Ed); 2019; 30(1):11-18. PubMed ID: 30143443
[TBL] [Abstract][Full Text] [Related]
3. Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study.
Ahn SH; Ahn SS; Park YW; Park CJ; Lee SK
Neuroradiol J; 2023 Feb; 36(1):49-58. PubMed ID: 35532193
[TBL] [Abstract][Full Text] [Related]
4. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
Kong Z; Zhang Y; Liu D; Liu P; Shi Y; Wang Y; Zhao D; Cheng X; Wang Y; Ma W
Ann Nucl Med; 2021 Apr; 35(4):493-503. PubMed ID: 33532992
[TBL] [Abstract][Full Text] [Related]
5. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A
Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
[TBL] [Abstract][Full Text] [Related]
8. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
11. Differential diagnosis of central lymphoma and high-grade glioma: dynamic contrast-enhanced histogram.
Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Feng YN; Wang MZ
Acta Radiol; 2020 Sep; 61(9):1221-1227. PubMed ID: 31902220
[TBL] [Abstract][Full Text] [Related]
12. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
13. The association between
Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
[TBL] [Abstract][Full Text] [Related]
14. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma.
Xie Z; Li J; Zhang Y; Zhou R; Zhang H; Duan C; Liu S; Niu L; Zhao J; Liu Y; Song S; Liu X
Front Neurosci; 2022; 16():1099019. PubMed ID: 36711137
[TBL] [Abstract][Full Text] [Related]
16. Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status.
Wang K; Li Y; Cheng H; Li S; Xiang W; Ming Y; Chen L; Zhou J
BMC Neurol; 2021 Nov; 21(1):460. PubMed ID: 34814870
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
Ulyte A; Katsaros VK; Liouta E; Stranjalis G; Boskos C; Papanikolaou N; Usinskiene J; Bisdas S
Neuroradiology; 2016 Dec; 58(12):1197-1208. PubMed ID: 27796446
[TBL] [Abstract][Full Text] [Related]
18. [The value of DCE-MRI in predicting IDH gene mutation of high-grade gliomas].
Lu HT; Xing W; Zhang YW; Qin HP; Wu RH; Ding JL
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(39):3105-3109. PubMed ID: 31648456
[No Abstract] [Full Text] [Related]
19. Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Regnery S; Behl NGR; Platt T; Weinfurtner N; Windisch P; Deike-Hofmann K; Sahm F; Bendszus M; Debus J; Ladd ME; Schlemmer HP; Rieken S; Adeberg S; Paech D
Neuroimage Clin; 2020; 28():102427. PubMed ID: 33002860
[TBL] [Abstract][Full Text] [Related]
20. Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status.
Hu Y; Zhang N; Yu MH; Zhou XJ; Ge M; Shen DD; Hua Y; Shi JL; Jia ZZ
Eur J Radiol; 2020 Oct; 131():109247. PubMed ID: 32891974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
